Saxagliptin + Metformin HydrochlorideThird Party Manufacturing in India

Saxagliptin + Metformin Hydrochloride is a fixed-dose combination that addresses three key pathophysiological defects of type 2 diabetes through two complementary mechanisms of action. Saxagliptin, a potent and selective DPP-4 inhibitor, works by preventing the degradation of incretin hormones GLP-1 and GIP. By maintaining higher levels of active GLP-1, saxagliptin enhances glucose-dependent insulin secretion from pancreatic beta-cells and suppresses glucagon release from alpha-cells, both of which help reduce blood glucose levels. Metformin Hydrochloride, a biguanide, works through a distinct but complementary mechanism. It primarily acts by decreasing hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis. Additionally, metformin improves peripheral insulin sensitivity by increasing glucose uptake and utilization in skeletal muscle and adipose tissue. It also delays intestinal glucose absorption. Together, this dual mechanism provides comprehensive glycemic control: saxagliptin addresses the incretin deficiency and impaired insulin secretion, while metformin targets insulin resistance and excessive hepatic glucose output. The combination allows for lower doses of each component, reducing the risk of dose-dependent side effects while achieving superior glycemic control compared to either agent alone. This fixed-dose combination is designed for once-daily administration with the extended-release metformin component providing a smooth pharmacokinetic profile.

Therapeutic Uses

Saxagliptin + Metformin Hydrochloride is prescribed for the treatment of:

• Type 2 Diabetes Mellitus: This fixed-dose combination is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on metformin alone or who are already being treated with saxagliptin and metformin as separate tablets. It addresses multiple defects of type 2 diabetes including insulin resistance, excessive hepatic glucose production, and impaired incretin-mediated insulin secretion.

• Add-on Combination Therapy: The combination is suitable for patients who require additional glycemic control beyond what metformin monotherapy provides. By adding saxagliptin, patients can achieve better HbA1c reduction without the weight gain or hypoglycemia risk associated with sulfonylureas.

• Step-up Therapy: For patients who have progressed from metformin monotherapy, this combination offers a convenient once-daily fixed-dose option that improves patient compliance compared to taking two separate medications.

Why Manufacturers Choose Saxagliptin + Metformin HCl

The saxagliptin + metformin combination represents a significant market opportunity in the Indian antidiabetic segment. Fixed-dose combinations of DPP-4 inhibitors with metformin are among the most prescribed diabetes medications globally, driven by their efficacy, safety profile, and convenience. This combination is particularly popular in India where the prevalence of type 2 diabetes is rapidly increasing. The availability of the combination as an extended-release formulation provides a competitive advantage in the marketplace. Indian manufacturers produce this combination for both the domestic PCD franchise market and for export to regulated and semi-regulated markets. The combination allows for product differentiation through branded generic formulations. With diabetes rates continuing to rise across developing economies, the demand for effective and affordable combination therapies is expected to remain strong. This makes Saxagliptin + Metformin one of the most sought-after combinations for third party manufacturing in India.